O2h signs agreement to provide discovery services to Karyopharm Therapeutics

O2h (Ahmedabad, India) is pleased to announce the signing of an agreement with Karyopharm Therapeutics, Inc. (Newton, Massachusetts, USA) under which O2h will provide Karyopharm discovery services to advance Karyopharm's lead small molecule program toward the nomination of a development candidate.

Dr. Sharon Shacham, co-founder and CSO of Karyopharm, said, "O2h has an excellent reputation as an efficient and high quality discovery services provider. We look forward to working with the O2h team to further the progress of our first program as we continue to build our proprietary expertise developing drugs targeting the nuclear pore complex machinery."

Sunil Shah, CEO of O2h, said, "It has been a pleasure working with Dr. Shacham as she is one of the most dynamic and focused drug discovery leaders that I have met. Leveraging Dr. Shacham's proprietary and proven approach to drug discovery, I'm optimistic that Karyopharm will be a great success."